Oragenics Inc (OGEN) 시세

From latest 10q and with $4mil in financing since... "The Company believes its working capital at September 30, 2024 will be sufficient to meet the business objectives as presently structured only through the fourth quarter of 2024. As such, there is substantial doubt that we can continue as a going concern beyond that date."...they burn thru $2.5-$3mil per quarter now b4 the trial starts...something gotta give...i'm not a hater by any means...imao..r

Obviously the 10k said something about needing more capital
What else is new clinical stage med tech land

Sooner or later they will need to do a RS…just a question if b4 or after the start of phase 2a trial announcement…running out of time to get over a buck … and they need funding if you read the 10k…imao…r

OGEN new 52/week low

OGEN: I lost--my-shirt today, behind this catastrophic 'fire storm' event!! (Can Trump please do a FLY-OVER to assess the damage --- and then otherwise do a Federal-Bailout for ME???!!!)

How did this not get halted today. Obvious P & D

They got me me fortunately only put 700 in it.  So dumb to chase these turds

Well Trump is here to help Day Traders. This could get ugly.

OGEN: I'm ashamed to admit this, but I grabbed $3K worth of this at $0.57 in the Pre-Market today --- totally abandoning my standard practice of seeing if it 'HAS ANY LEGS' in the Open-Market today. (To paraphrase one of the Orion's Board's legendary Founding Fathers --- 'Monk', or 'Augusta'??)

I'm PRAYING hard right now --- see ME below, live --- for circa $1.50 here, a little later today. (Heck, whatever WORKS --- right??)

OGEN..................................https://stockcharts.com/h-sc/ui?s=OGEN&p=W&b=5&g=0&id=p86431144783

OGEN: Unusual PR here ---
https://finance.yahoo.com/news/oragenics-inc-chief-medical-officer-131500235.html

Obviously, they are trying to exploit & capitalize upon the NFL fears of BRAIN injuries:

"advancing innovative treatments for concussion and brain-related health conditions"

OGEN: Hot-off-the-PRESS!!! What kind of news is this???!!!

"Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025"

OGEN: And all behind NOT DUMPING MORE SHARES, purported "news".

The best premarket runner .59 + 107%

OGEN: See its Post-M 'CHART', below!!

And all behind the following Ages-Old TRICK, to desperately get your Firm's stock PRICE to go UP for once!!
"DJ Oragenics Withdraws Filing for a Securities Offering"

I have various scans set up to alert me…🥳

Curious as to how would've you been alerted to this when at 4:00`, it closed at .325 down .01 ?

Who's excited...🥳...its just a flip...

Don't get too excited, purely a manipulation (hence aftermarket) by Dawson James to do a financing, I'm sure you'll see the 8k tomorrow or Friday. JMHO

OGEN...58s clearing on volume...🥳

OGEN 10Q due 11/11

Dilution at 55 cents. Sell.

Oragenics Inc. ($OGEN) is a healthcare innovator focusing on novel antibiotics and treatments for oral mucositis. With a 52-week range of $0.86 to $7.74, it is advancing products like OG716, LBPs, and Terra CoV-2 immunization.

WOW more weak hands. And with only 5.6 mil os :)

The average one-year price target for Oragenics, Inc. is $91.80. :)

Weak many hands are gone, new investors welcome. :)

Weak many hands are gone, new investors welcome. :)

Not for long. :)

OGEN under $2

OGEN under $2

OGEN 10Q due 3/19

China Dump

News just hit! Oragenics Issues Update to Shareholders:
https://www.otcmarkets.com/stock/OGEN/news/story?e&id=2676834

OGEN steady rise looks like this biotech is ready to run!

Will this turd float to the surface? :)

Maybe not. :)

Don't madder they will short it down to nothing

Surfs up. ::)

Chart setup perfectly here -> time is koming for the super spike

https://stockcharts.com/h-sc/ui?s=ogen

Hey whatever it takes to see it rise to the moon but wow hats off to your sacrifice. :)

,,,,,,,I’m out

3/22 Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1

"“We are thrilled to have begun this pivotal study with Frontage, a premier drug development contract research organization, and are thankful to the acceleration Frontage has offered our important IND-enabling study. We believe the results from this rabbit toxicology study will support our development strategy for our intranasal COVID-19 vaccine candidate, NT-CoV2-1. The intranasal delivery route is particularly relevant as it may further reduce transmission of the virus and provide a needle-free delivery option. The findings from this preclinical toxicology study will be a part of our Investigational New Drug filing to the U.S. Food and Drug Administration,” said Frederick W. Telling, Ph.D., Executive Chairman of Oragenics."


https://ir.oragenics.com/press-releases/detail/142

KABOOM !! ve got movement!!

Looks like word is getting out. :)

I agree. The buy consensus is at 83%.3 days ago. I think info is near. :)

HUGE insider buy

OGEN HOD

lets get this back over $1

Oragenics (OGEN) Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant

Agreement extends current licensing and collaboration agreement to include rapid production of Omicron-specific intranasal vaccine candidates

TAMPA, Fla., December 20, 2021--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") today announced it has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue an intranasal vaccine designed to protect against the SARS-CoV-2 Omicron variant. The NRC cell expression technologies provide Oragenics with a platform that can generate cell lines for high-yield production of spike protein antigens for existing and emerging variants of concern. This platform should allow production of cell lines within six to eight weeks of spike gene sequence availability, compared with six to nine months for traditional production of such cell lines. The NRC technologies, developed with support from the NRC’s Pandemic Response Challenge program, will expedite the evaluation of an Omicron-specific Terra-CoV-2 candidate in preclinical and clinical studies.

"Oragenics is well-positioned to develop an Omicron-specific intranasal vaccine thanks to our successful, on-going collaboration with the NRC," said Frederick W. Telling, Ph.D., Oragenics’ Executive Chairman. "We had anticipated the need for rapid development of COVID-19 vaccine candidates against new variants and can leverage the NRC cell expression platform to address Omicron and future variants."

Oragenics recently demonstrated the protection of hamsters against SARS-CoV-2 with the intranasal Terra-CoV-2 candidate, which strongly supports the further development into an IND-enabling GLP toxicology study and a first-in-human Phase 1 clinical study.

https://finance.yahoo.com/news/oragenics-extends-collaboration-national-research-130000929.html

Oragenics Announces Positive COVID-19 Challenge Study Results

Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") today announced the results from its study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study. The study provided preclinical data for formulations designed for both intranasal and intramuscular administration.

Both formulations generated robust immune responses and reduced the SARS-CoV-2 viral loads to undetectable levels in the nasal passages and lungs five days following a viral challenge. By contrast, hamsters in the control groups that had received saline or adjuvants alone had no detectable immune response and substantial viral loads. The vaccines delivered by intranasal and intramuscular routes generated immune responses as measured by multiple assays.

"The very positive results from this hamster challenge study fully support our further development of either the intranasal or intramuscular routes of administration, however we plan to focus on the intranasal delivery route for the Terra CoV-2 vaccine due to the relative lack of competition and anticipated advantages of intranasal vaccine delivery, such as reducing viral transmission, needle-free administration, and ease of distribution, as well as the potential for conferred mucosal immunity which is presently being studied. The findings from this second preclinical study will be a part of our Investigational New Drug filing to the U.S. Food and Drug Administration, expected to be made in the second quarter of 2022, and should facilitate advancement of the program into human clinical studies," said Frederick W. Telling, Ph.D., Executive Chairman of Oragenics.

https://finance.yahoo.com/news/oragenics-announces-positive-covid-19-130000711.html